A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]

Inclusion Criteria: * Diagnosis of NSCLC with confirmed squamous or non-squamous tumour histology, without known epidermal growth factor receptor (EGFR) mutation * Advanced or metastatic disease (Stage IIIb or IV) * Patients to be treated with cisplatin/gemcitabine or cisplatin/pemetrexed: No previous systemic treatment with chemotherapy, targeted therapy or investigational agents (except adjuvant therapy if \> 6 months ago); Patients to be treated with docetaxel: ≥ 1 previous treatment with chemotherapy * Measurable disease by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria * ECOG performance score 0-1 * Life expectancy ≥ 3 months * Adequate bone marrow-, renal- and hepatic function * LVEF ≥ 55% on cardiac ultrasound Exclusion Criteria: * Symptomatic brain metastases * Gastro-intestinal disorders that could affect drug absorption (including, but not limited to, major abdominal surgery, significant bowel obstruction, ulcerative colitis, Crohn's disease) * Concurrent treatment with any other systemic anti-cancer therapy * Serious concomitant uncontrolled medical conditions